Brief: Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval
27/03/2026 12:03
March 27 (Reuters) - Sanofi SA SASY.PA: SANOFI’S SARCLISA SUBCUTANEOUS FORMULATION ADMINISTERED VIA ON-BODY INJECTOR RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT MULTIPLE MYELOMA IF APPROVED, SARCLISA SUBCUTANEOUS (SC) WOULD BE FIRST AVAILABLE ANTICANCER TREATMENT TO BE ADMINISTERED THROUGH AN ON-BODY INJECTOR, FIRST MULTIPLE MYELOMA MEDICINE AVAILABLE BY BOTH SC OBI, MANUAL INJECTION IN EU RECOMMENDATION BASED ON POSITIVE RESULTS DEMONSTRATING COMPARABLE EFFICACY, PHARMACOKINETICS, AND SAFETY OF SARCLISA REGIMENS ADMINISTERED SUBCUTANEOUSLY COMPARED TO INTRAVENOUS INFUSION Source text: ID:nGNX14TDK0 Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes